丽珠医药(01513):完带汤颗粒获得《药品注册证书》

智通财经
Oct 27

智通财经APP讯,丽珠医药(01513)发布公告,近日,丽珠医药集团股份有限公司(本公司)的子公司四川光大制药有限公司(四川光大)就完带汤颗粒(本品)的药品注册申请收到国家药品监督管理局签发的《药品注册证书》(证书编号:2026S03950)。

本品处方源自清代傅山所著《傅青主女科》,已列入国家中医药管理局《古代经典名方目录(第一批)》。据典籍原文记载,本方为治疗带下病的经典方剂,其功能主治为“补脾疏肝,化湿止带。用于带下病,肝郁脾虚、湿浊下注证。症见带下色白或淡黄,清稀无臭,面色㿠白,倦怠便溏,舌淡苔白,脉缓或濡弱”,方剂核心治疗思路为补脾疏肝,化湿止带。

该方剂在历代女科医案屡有记载,现代亦开展多项临床与实验研究,被《方剂学》规划教材收录;作为妇科常用方,广泛应用于带下量多清稀及慢性盆腔炎、阴道炎、宫颈炎等属脾虚湿盛者。

截至本公告披露日,完带汤颗粒累计直接投入的研发费用约为人民币447.46万元。

本品为国内首家获批上市,同时也是本公司获批的第二款3.1类新药,进一步丰富本公司产品管线,有助于提升本公司产品的市场竞争力。本品上市后,可推动经典名方在临床中大范围应用,有助于提升中医临床诊疗服务能力,同时提升患者用药便捷性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10